Kuo et al. reported that pharmacological and genetic inactivation of NPY2R led to a reduction in adipogenesis and abdominal obesity, providing support for NPY-NPYR-based drugs as candidate anti-obesity-therapeutics (36). This evidence concerns the gene NPY1R and obesity due to melanocortin 4 receptor deficiency.